These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 20331473)

  • 41. A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus.
    Martina BE; van den Doel P; Koraka P; van Amerongen G; Spohn G; Haagmans BL; Provacia LB; Osterhaus AD; Rimmelzwaan GF
    PLoS One; 2011 Apr; 6(4):e18995. PubMed ID: 21541326
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations.
    Van Hoeven N; Joshi SW; Nana GI; Bosco-Lauth A; Fox C; Bowen RA; Clements DE; Martyak T; Parks DE; Baldwin S; Reed SG; Coler RN
    PLoS One; 2016; 11(2):e0149610. PubMed ID: 26901122
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Induction of sterilizing immunity against West Nile Virus (WNV), by immunization with WNV-like particles produced in insect cells.
    Qiao M; Ashok M; Bernard KA; Palacios G; Zhou ZH; Lipkin WI; Liang TJ
    J Infect Dis; 2004 Dec; 190(12):2104-8. PubMed ID: 15551208
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Newcastle disease virus-vectored West Nile fever vaccine is immunogenic in mammals and poultry.
    Wang J; Yang J; Ge J; Hua R; Liu R; Li X; Wang X; Shao Y; Sun E; Wu D; Qin C; Wen Z; Bu Z
    Virol J; 2016 Jun; 13():109. PubMed ID: 27342050
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step.
    Vogt MR; Moesker B; Goudsmit J; Jongeneelen M; Austin SK; Oliphant T; Nelson S; Pierson TC; Wilschut J; Throsby M; Diamond MS
    J Virol; 2009 Jul; 83(13):6494-507. PubMed ID: 19386704
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Supramolecular peptide hydrogel adjuvanted subunit vaccine elicits protective antibody responses against West Nile virus.
    Friedrich BM; Beasley DWC; Rudra JS
    Vaccine; 2016 Nov; 34(46):5479-5482. PubMed ID: 27670075
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01.
    Iyer AV; Pahar B; Boudreaux MJ; Wakamatsu N; Roy AF; Chouljenko VN; Baghian A; Apetrei C; Marx PA; Kousoulas KG
    Vaccine; 2009 Feb; 27(6):893-903. PubMed ID: 19070640
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetically delivered antibody protects against West Nile virus.
    Pereboev A; Borisevich V; Tsuladze G; Shakhmatov M; Hudman D; Kazachinskaia E; Razumov I; Svyatchenko V; Loktev V; Yamshchikov V
    Antiviral Res; 2008 Jan; 77(1):6-13. PubMed ID: 17904654
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prospective immunization of the endangered California condors (Gymnogyps californianus) protects this species from lethal West Nile virus infection.
    Chang GJ; Davis BS; Stringfield C; Lutz C
    Vaccine; 2007 Mar; 25(12):2325-30. PubMed ID: 17224209
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recovery of West Nile Virus Envelope Protein Domain III Chimeras with Altered Antigenicity and Mouse Virulence.
    McAuley AJ; Torres M; Plante JA; Huang CY; Bente DA; Beasley DWC
    J Virol; 2016 May; 90(9):4757-4770. PubMed ID: 26912625
    [TBL] [Abstract][Full Text] [Related]  

  • 51. West Nile Virus Vaccine Design by T Cell Epitope Selection:
    Waller FM; Reche PA; Flower DR
    J Immunol Res; 2020; 2020():7235742. PubMed ID: 32258174
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vaccine-induced protection of rhesus macaques against plasma viremia after intradermal infection with a European lineage 1 strain of West Nile virus.
    Verstrepen BE; Oostermeijer H; Fagrouch Z; van Heteren M; Niphuis H; Haaksma T; Kondova I; Bogers WM; de Filette M; Sanders N; Stertman L; Magnusson S; Lőrincz O; Lisziewicz J; Barzon L; Palù G; Diamond MS; Chabierski S; Ulbert S; Verschoor EJ
    PLoS One; 2014; 9(11):e112568. PubMed ID: 25392925
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of chimaeric West Nile virus attenuated vaccine candidate based on the Japanese encephalitis vaccine strain SA14-14-2.
    Li XF; Zhao W; Lin F; Ye Q; Wang HJ; Yang D; Li SH; Zhao H; Xu YP; Ma J; Deng YQ; Zhang Y; Qin ED; Qin CF
    J Gen Virol; 2013 Dec; 94(Pt 12):2700-2709. PubMed ID: 24092759
    [TBL] [Abstract][Full Text] [Related]  

  • 54. West Nile virus-specific CD4 T cells exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection.
    Brien JD; Uhrlaub JL; Nikolich-Zugich J
    J Immunol; 2008 Dec; 181(12):8568-75. PubMed ID: 19050276
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comprehensive mapping of West Nile virus (WNV)- and Japanese encephalitis virus serocomplex-specific linear B-cell epitopes from WNV non-structural protein 1.
    Sun EC; Zhao J; Liu NH; Yang T; Ma JN; Geng HW; Wang LF; Qin YL; Bu ZG; Yang YH; Lunt RA; Wang LF; Wu DL
    J Gen Virol; 2012 Jan; 93(Pt 1):50-60. PubMed ID: 21940411
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice.
    Dunn MD; Rossi SL; Carter DM; Vogt MR; Mehlhop E; Diamond MS; Ross TM
    Virol J; 2010 May; 7():95. PubMed ID: 20462412
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The structural immunology of antibody protection against West Nile virus.
    Diamond MS; Pierson TC; Fremont DH
    Immunol Rev; 2008 Oct; 225():212-25. PubMed ID: 18837784
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative efficacies of three commercially available vaccines against West Nile Virus (WNV) in a short-duration challenge trial involving an equine WNV encephalitis model.
    Seino KK; Long MT; Gibbs EP; Bowen RA; Beachboard SE; Humphrey PP; Dixon MA; Bourgeois MA
    Clin Vaccine Immunol; 2007 Nov; 14(11):1465-71. PubMed ID: 17687109
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus.
    Shrestha B; Ng T; Chu HJ; Noll M; Diamond MS
    Vaccine; 2008 Apr; 26(16):2020-33. PubMed ID: 18339459
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunogenicity and efficacy of two types of West Nile virus-like particles different in size and maturation as a second-generation vaccine candidate.
    Ohtaki N; Takahashi H; Kaneko K; Gomi Y; Ishikawa T; Higashi Y; Kurata T; Sata T; Kojima A
    Vaccine; 2010 Sep; 28(40):6588-96. PubMed ID: 20678586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.